Publications
Featured Publications
Interleukin-18 Engineered For Resistance to IL-18 Binding Protein (IL-18BP) and Half-Life Extension to Enhance Its Therapeutic Potential
American Association for Cancer Research (AACR) Annual Meeting
April 2024
Generation of tumor targeted self-assembling split IL-12p35 and IL-12p40 subunits for the treatment of cancer
American Association for Cancer Research (AACR) Annual Meeting
April 2024
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
All Publications
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
Journal for ImmunoTherapy of Cancer
March 2020
ARTISTRY-2: A Phase 1/2 Study of Subcutaneously Administrated ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2019
Intravenous Administration of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in a Phase 1/2 Study of Patients With Advanced Solid Tumors
American Society of Clinical Oncology (ASCO) Annual Meeting
May 2019
Peripheral Blood Lymphocyte Response to High Dose IL2 in RCC
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2018
Pharmacokinetics and Pharmacodynamic Effects of ALKS 4230, an Investigational Immunotherapeutic Agent, in Cynomolgus Monkeys After Intravenous and Subcutaneous Administration
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2018
Safety, Pharmacokinetics, and Pharmacodynamic Effects of ALKS 4230 in Patients With Advanced Solid Tumors From the Ongoing Dose Escalation Portion of a First In Human (FIH) Study
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2018
A Novel, Individualized Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by ALKS 4230
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2017
A Phase 1 Trial of ALKS 4230, an Engineered Cytokine Activator of NK and Effector T Cells, in Patients with Advanced Solid Tumors
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2017
First-In-Human Dose Selection for ALKS 4230, an Investigational Immunotherapeutic Agent
American Association for Cancer Research (AACR) Annual Meeting
April 2017
Efficacy of ALKS 4230, a Novel Immunotherapeutic Agent, in Murine Syngeneic Tumor Models Alone and in Combination with Immune Checkpoint Inhibitors
American Association for Cancer Research (AACR) Annual Meeting
April 2017
Characterization of the Pharmacodynamic Immune Response to a Novel Immunotherapeutic Agent, ALKS 4230, in Mice and Non-Human Primates
American Association for Cancer Research (AACR) Annual Meeting
April 2017